ACR urges the FTC to thoroughly examine the impact of pharmacy benefit managers on prescription drug costs and access for people living with rheumatic disease

In comments submitted to the Federal Trade Commission (FTC), the American College of Rheumatology (ACR) urged the agency to address Pharmacy Benefit Manager (PBM) business practices that drive up costs and reduce access for the 54 million Americans living with rheumatic disease. “The FTC’s decision to study PBM business practices is an important step toward enacting meaningful reforms that reduce costs and […]